Vitamin C Infusion for Treatment in Sepsis Induced Acute Lung Injury
Status:
Completed
Trial end date:
2018-01-08
Target enrollment:
Participant gender:
Summary
Hypothesis 1A: Vitamin C infusion will significantly attenuate sepsis-induced systemic organ
failure as measured by Sequential Organ Failure Assessment (SOFA) score,
Hypothesis 1B: Vitamin C infusion will attenuate sepsis-induced lung injury as assessed by
the oxygenation index and the VE40
Hypothesis 1C: Vitamin C infusion will attenuate biomarkers of inflammation (C-Reactive
Protein, Procalcitonin), vascular injury (Thrombomodulin, Angiopoietin-2), alveolar
epithelial injury (Receptor for Advanced Glycation Products), while inducing the onset of a
fibrinolytic state (Tissue Factor Pathway Inhibitor).